| INTRODUC TI ON
In Japan, lung cancer accounts for approximately 20% of all cancerrelated deaths (approximately 77 200 in 2015) and is the leading cause of cancer-related mortality in men (25% of all cancer deaths) and the second leading cause of cancer-related mortality in women (14% of all cancer deaths).
1 Standard-of-care therapy for patients with advanced non-small-cell lung cancer (NSCLC) without sensitizing EGFR or ALK aberrations has typically comprised first-line platinum-based chemotherapy followed by single-agent cytotoxic chemotherapy. 2 Patients with sensitizing EGFR mutations or ALK aberrations may receive inhibitors targeting these molecules (ie, EGFR tyrosine kinase inhibitors and ALK inhibitors).
2
The advent of immunotherapy has provided patients with NSCLC with treatment options that can significantly improve outcomes, with a manageable safety profile. Pembrolizumab is a highly selective, humanized monoclonal antibody against the programmed death 1 (PD-1) receptor, which inhibits its interaction with its ligands, programmed death ligand 1 (PD-L1) and 2. 3 In the international phase 2/3 KEYNOTE-010 study in patients with previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥1%, pembrolizumab 2 mg/kg or 10 mg/kg every 3 weeks (Q3W) was shown to significantly improve overall survival (OS) compared with docetaxel and had a favorable benefit-risk profile. 4 Among patients with a PD-L1 TPS ≥1%, hazard ratios (HR) for OS for pembrolizumab 2 mg/kg Q3W and 10 mg/kg Q3W versus docetaxel were .71 (95% CI, .58-.88; P = .0008) and .61 (95% CI, .49-.75; P < .0001),
respectively. Among patients with PD-L1 TPS ≥50%, HR (95% CI) for OS for pembrolizumab 2 and 10 mg/kg Q3W versus docetaxel were .54 (.38-.77; P = .0002) and .50 (.36-.70; P < .0001), respectively. In the first-line setting, pembrolizumab 200 mg Q3W has been shown to improve OS and progression-free survival (PFS) compared with platinum-based chemotherapy in patients with advanced NSCLC with PD-L1 TPS ≥50% without sensitizing EGFR or ALK aberrations in the phase 3 KEYNOTE-024 study 5 and to improve OS and PFS when combined with platinum-pemetrexed compared with placebo plus platinum-pemetrexed in the phase 3 KEYNOTE-189 study 6 ; in both studies, toxicity was manageable.
The phase 1b KEYNOTE-025 study (ClinicalTrials.gov identifier, NCT02007070) was conducted in Japan and evaluated the efficacy and safety of pembrolizumab in patients with previously treated PD-L1-expressing advanced NSCLC. Some recent evidence has suggested that efficacy and toxicity outcomes for Asian patients receiving systemic therapy for lung cancer may differ from those of Caucasian patients. 7, 8 Herein, we report efficacy and safety outcomes from Japanese patients that received pembrolizumab in the KEYNOTE-025 study.
| ME THODS

| Eligibility
Patients ≥20 years old were eligible if they had a histologically or cy- 
| Assessments
Radiographic imaging (computed tomography or magnetic resonance imaging) was done at baseline and every 9 weeks thereafter.
Response was assessed per irRC by investigators and per RECIST 
| Statistical analysis
It was determined that with 12 patients in the primary analysis population (patients with PD-L1 TPS ≥50%), an assumed response rate of 50% and a 1-sided significance level of .025, the study would have 80% power to demonstrate that the response rate was significantly 
| RE SULTS
| Patients
Between had completed 2 years of treatment. In total, 33 patients (87%) discontinued treatment as a result of disease progression (n = 25; 66%), AE (n = 4; 11%), received medication not permitted per the study protocol (n = 2; 5%), death (n = 1; 3%) and physician decision (n = 1; 3%); study medication status was not recorded for 2 patients (5%).
Median (range) duration of follow up was 19.2 (1.9-34.6) months.
Baseline characteristics are summarized in Table 1 . Median (range) age was 66 (41-78) years, 26 patients (68%) were male and 26 patients (68%) had an ECOG performance status of 1. Twenty-three patients (61%) had received ≥2 prior systemic therapies, and 29 (76%) had adenocarcinoma histology.
| Safety
Overall, 33 patients (87%) had a treatment-related AE of any grade, with 11 (29%) experiencing ≥1 grade 3 to 5 treatment-related AE (Table 2 ). The most frequently occurring treatment-related AE were malaise (21%), diarrhea (16%) and maculopapular rash (16%). Nine patients (24%) had grade 3 treatment-related AE; none occurred in >1 patient with the exception of decreased lymphocyte count (n = 2).
Treatment-related grade 4 and 5 AE were optic neuritis (n = 1; grade 4) and interstitial lung disease (n = 1; grade 5).
Immune-mediated AE and infusion reactions (regardless of attribution to study treatment or immune relatedness by the investigator) occurred in 9 patients (24%; Table 2 ). The most frequently occurring of these were pneumonitis (n = 4; grade 5, n = 1), hypothyroidism at day 104; not resolved) and 2 cases of interstitial lung disease (1 of grade 2 [onset at day 16; resolved after 17 days] and 1 of grade 5
[described above]).
| Efficacy
This study did not meet the pre-defined primary endpoint ORR criteria (ie, that the lower limit of the 95% CI for ORR among patients with PD-L1 TPS ≥50% would be greater than 15%; see Methods). Among the 11 evaluable patients with PD-L1 TPS ≥50%, 3 had a partial response and the confirmed ORR was 27% (95% CI, 6-61); the lower limit of the 95% CI for ORR in this group was lower than the threshold of 15%. The median duration of response was not reached (range,
14.9-29.1 [ongoing] months). Among the 37 patients with PD-L1 TPS
≥1% who were evaluable for response, 8 had a partial response and none had a complete response ( Table 3 ). The confirmed ORR was 22% (95% CI, 10-38). Median duration of response was 22.8 months months, and the 6-month PFS rate was 42% ( Figure 4A ). Thirty-three of 38 (87%) patients with PD-L1 TPS ≥1% had PFS events. The median (95% CI) PFS was 3.9 (2.0-6.2) months, and the 6-month PFS rate was 40%. Nine patients (75%) with PD-L1 TPS ≥50% and 26 patients (68%) with PD-L1 TPS ≥1% had died. The median (95% CI)
OS in patients with PD-L1 TPS ≥50% and TPS ≥1% were 17.9 (5.9-not reached) and 19.2 (8.0-26.7) months, respectively. One-year OS rates for patients with PD-L1 TPS ≥50% and TPS ≥1% were 67% and 58%, respectively ( Figure 4B ).
Efficacy analyses in subgroups defined by select patient baseline characteristics are shown in Table S1 . ORR was 15% (95% CI, 2-45) among patients who had never smoked (n = 12) and 25% (95% CI, 10-47) among former smokers (n = 26). ORR was similar in patients with adenocarcinoma histology (18% [95% CI, 6-37]; n = 29) and squamous histology (17% [95% CI, .4-64]; n = 6). Notably, among the 10 patients with EGFR mutations (all of whom had adenocarcinoma histology; Table S1 ) and the 2 patients with ALK translocations, none had a response (Figure 1 ). Among patients with wild-type EGFR and adenocarcinoma histology (n = 19), the ORR was 29.6% (95% CI, 14-50). In addition, the median PFS and OS appeared to be nominally shorter among patients with EGFR mutation versus adenocarcinoma patients without an EGFR mutation (Table S1 ).
| D ISCUSS I ON
In this phase 1b study, pembrolizumab 10 mg/kg once Q3W had promising antitumor activity and was well tolerated in Japanese patients with previously treated advanced NSCLC with a PD-L1 TPS ≥1%. The safety profile of pembrolizumab in this study was generally similar to that reported in previous studies evaluating pembrolizumab monotherapy in patients with advanced NSCLC. 4, 5, 10 The finding that pembrolizumab was well tolerated in Japanese patients is consistent with results from the KEYNOTE-041 study, which found pembrolizumab to be well tolerated in Japanese patients with advanced melanoma. 13 The most common treatment-related AE in our study were malaise, diarrhea and rash. As in other studies evaluating pembrolizumab monotherapy in patients with NSCLC, 14 In KEYNOTE-041, which enrolled only Japanese patients with advanced melanoma (N = 42), 1 patient (2.4%) who received pembrolizumab experienced pneumonitis (grade 2). 13 In a metaanalysis, 15 the incidence of pneumonitis of any grade among patients receiving anti-PD-1 monotherapy was found to be 2.7% (95% CI, 1.9%-3.6%; N = 4496). Given the number of patients enrolled in our study (N = 38), it is difficult to definitively determine whether pneumonitis events occurred more frequently in our Japanese study population. However, given the potential risks associated with this toxicity, it is important for physicians to recognize its symptoms and risk factors. 16, 17 Treatment with pembrolizumab 10 mg/kg Q3W in this study was associated with clinically meaningful antitumor activity. Among patients with PD-L1 TPS ≥50%, the ORR (95% CI) was 27.3% (6-61), whereas among patients with PD-L1 TPS ≥1%, the ORR was 22%
(10-38). Moreover, most patients (73.0%) had a reduction in tumor burden from baseline, and responses were durable; at data cutoff, the median duration of response had not been reached among patients who responded to therapy in the PD-L1 TPS ≥50% group, and the response duration was 22.8 months for patients with a response in the PD-L1 TPS ≥1% group. These outcomes are consistent with those reported in the international multicenter phase 2/3 KEYNOTE-010 study 4 and in the phase 1 KEYNOTE-001 study (although it should be noted that KEYNOTE-001 enrolled both previously treated and treatment-naive patients). 10 Although ORR in our study was nominally higher among the subgroup of patients with PD-L1 TPS ≥50%
versus the overall study population, there was little evidence of a difference in PFS or OS at these different PD-L1 cutoffs. Moreover, median PFS and OS in our study were similar to those previously reported in the KEYNOTE-010 study, both among patients with PD-L1 TPS ≥1% and patients with PD-L1 TPS ≥50%. 4 In the first-line setting, pembrolizumab 200 mg has been shown to improve OS, PFS and ORR compared with platinum-based chemotherapy among patients with NSCLC with PD-L1 TPS ≥50% (although it should be noted that these data are not directly comparable with those from this study owing to differences in study population). 
20
Given that target saturation appears to occur with pembrolizumab doses greater than approximately 1 mg/kg, 21, 22 outcomes in this study are unlikely to be different to those that would be achieved with the fixed dose.
In summary, pembrolizumab was generally well tolerated in Japanese patients with previously treated PD-L1-positive advanced NSCLC, but pneumonitis should be carefully monitored.
Pembrolizumab showed promising antitumor activity in this setting; outcomes were consistent with those from large phase 3 studies. These results support the use of pembrolizumab in Japanese patients with previously treated PD-L1-positive advanced NSCLC. 
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